367 related articles for article (PubMed ID: 18559596)
1. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
Kube D; Hua TD; von Bonin F; Schoof N; Zeynalova S; Klöss M; Gocht D; Potthoff B; Tzvetkov M; Brockmöller J; Löffler M; Pfreundschuh M; Trümper L
Clin Cancer Res; 2008 Jun; 14(12):3777-84. PubMed ID: 18559596
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma.
Bogunia-Kubik K; Mazur G; Wróbel T; Kuliczkowski K; Lange A
Tissue Antigens; 2008 Feb; 71(2):146-50. PubMed ID: 18201362
[TBL] [Abstract][Full Text] [Related]
3. The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma.
Kube D; Hua TD; Klöss M; Kulle B; Brockmöller J; Wojnowski L; Löffler M; Pfreundschuh M; Trümper L
Genes Immun; 2007 Mar; 8(2):164-7. PubMed ID: 17215862
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.
Lee JJ; Kim DH; Lee NY; Sohn SK; Kim JG; Kim HJ; Do YR; Park YH
Br J Haematol; 2007 May; 137(4):329-36. PubMed ID: 17408400
[TBL] [Abstract][Full Text] [Related]
5. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
[TBL] [Abstract][Full Text] [Related]
6. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
Park YH; Sohn SK; Kim JG; Lee MH; Song HS; Kim MK; Jung JS; Lee JJ; Kim HJ; Kim DH
Clin Cancer Res; 2009 Mar; 15(6):2107-15. PubMed ID: 19276283
[TBL] [Abstract][Full Text] [Related]
7. Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms.
Domingo-Domènech E; Benavente Y; González-Barca E; Montalban C; Gumà J; Bosch R; Wang SS; Lan Q; Whitby D; Fernández de Sevilla A; Rothman N; de Sanjosé S
Haematologica; 2007 Nov; 92(11):1475-81. PubMed ID: 18024395
[TBL] [Abstract][Full Text] [Related]
8. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
Pedersen LM; Klausen TW; Davidsen UH; Johnsen HE
Ann Hematol; 2005 Aug; 84(8):510-6. PubMed ID: 15834569
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection.
Persico M; Capasso M; Persico E; Masarone M; Renzo Ad; Spano D; Bruno S; Iolascon A
J Hepatol; 2006 Dec; 45(6):779-85. PubMed ID: 17049666
[TBL] [Abstract][Full Text] [Related]
10. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
11. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
Ozdemir F; Aydin F; Yilmaz M; Kavgaci H; Bektas O; Yavuz MN; Yavuz AA
J Exp Clin Cancer Res; 2004 Sep; 23(3):485-8. PubMed ID: 15595640
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
[TBL] [Abstract][Full Text] [Related]
13. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95.
Seidemann K; Zimmermann M; Book M; Meyer U; Burkhardt B; Welte K; Reiter A; Stanulla M
J Clin Oncol; 2005 Nov; 23(33):8414-21. PubMed ID: 16293872
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients.
Mazur G; Bogunia-Kubik K; Wrobel T; Kuliczkowski K; Lange A
Cytokine; 2006 Feb; 33(3):145-9. PubMed ID: 16524740
[TBL] [Abstract][Full Text] [Related]
16. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma.
Snoussi K; Strosberg AD; Bouaouina N; Ben Ahmed S; Chouchane L
Eur Cytokine Netw; 2005 Dec; 16(4):253-60. PubMed ID: 16464738
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma.
Schoof N; Franklin J; Fürst R; Zander T; von Bonin F; Peyrade F; Trümper L; Diehl V; Engert A; Kube D; Re D
Oncologist; 2013; 18(1):80-9. PubMed ID: 23299779
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma.
Fernberg P; Chang ET; Duvefelt K; Hjalgrim H; Eloranta S; Sørensen KM; Porwit A; Humphreys K; Melbye M; Ekström Smedby K
Cancer Causes Control; 2010 May; 21(5):759-69. PubMed ID: 20087644
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms within glutathione S-transferase genes in pediatric non-Hodgkin's lymphoma.
Dieckvoss BO; Stanulla M; Schrappe M; Beier R; Zimmermann M; Welte K; Reiter A
Haematologica; 2002 Jul; 87(7):709-13; discussion 713. PubMed ID: 12091121
[TBL] [Abstract][Full Text] [Related]
20. No substantial difference in genotype frequencies of interleukin and myeloperoxidase polymorphisms between malignant lymphoma patients and non-cancer controls.
Matsuo K; Hamajima N; Suzuki R; Nakamura S; Seto M; Morishima Y; Tajima K
Haematologica; 2001 Jun; 86(6):602-8. PubMed ID: 11423389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
